Logo image of HEB

HEMISPHERX BIOPHARMA INC (HEB) Stock Price, Quote, News and Overview

NYSEARCA:HEB - NYSE Arca -

1.8  -0.01 (-0.55%)

After market: 1.77 -0.03 (-1.67%)

HEB Quote, Performance and Key Statistics

HEMISPHERX BIOPHARMA INC

NYSEARCA:HEB (8/30/2019, 8:05:43 PM)

After market: 1.77 -0.03 (-1.67%)

1.8

-0.01 (-0.55%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High14.81
52 Week Low1.69
Market Cap4.40M
Shares2.44M
Float1.05M
Yearly Dividend0
Dividend Yield0%
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A N/A


HEB short term performance overview.The bars show the price performance of HEB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

HEB long term performance overview.The bars show the price performance of HEB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of HEB is 1.8 null. In the past month the price decreased by -19.28%. In the past year, price decreased by -85.12%.

HEMISPHERX BIOPHARMA INC / HEB Daily stock chart

About HEB

Company Profile

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.

Company Info

HEMISPHERX BIOPHARMA INC

2117 SW HIGHWAY 484

OCALA FL 34473

CEO: Thomas K. Equels

Phone: 215-988-0080

HEMISPHERX BIOPHARMA INC / HEB FAQ

What is the stock price of HEMISPHERX BIOPHARMA INC today?

The current stock price of HEB is 1.8 null. The price decreased by -0.55% in the last trading session.


What is the ticker symbol for HEMISPHERX BIOPHARMA INC stock?

The exchange symbol of HEMISPHERX BIOPHARMA INC is HEB and it is listed on the NYSE Arca exchange.


On which exchange is HEB stock listed?

HEB stock is listed on the NYSE Arca exchange.


What is HEMISPHERX BIOPHARMA INC worth?

HEMISPHERX BIOPHARMA INC (HEB) has a market capitalization of 4.40M null. This makes HEB a Nano Cap stock.


What are the support and resistance levels for HEMISPHERX BIOPHARMA INC (HEB) stock?

HEMISPHERX BIOPHARMA INC (HEB) has a resistance level at 1.93. Check the full technical report for a detailed analysis of HEB support and resistance levels.


Should I buy HEMISPHERX BIOPHARMA INC (HEB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HEMISPHERX BIOPHARMA INC (HEB) stock pay dividends?

HEB does not pay a dividend.


What is the Price/Earnings (PE) ratio of HEMISPHERX BIOPHARMA INC (HEB)?

HEMISPHERX BIOPHARMA INC (HEB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.54).


HEB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HEB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HEB. HEB has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HEB Financial Highlights

Over the last trailing twelve months HEB reported a non-GAAP Earnings per Share(EPS) of -5.540000000000001. The EPS decreased by -2418.18% compared to the year before.


Industry RankSector Rank
PM (TTM) -3284.04%
ROA -73.02%
ROE -153.97%
Debt/Equity 0.37
Chartmill High Growth Momentum
EPS Q2Q%-2040%
Sales Q2Q%-12.12%
EPS 1Y (TTM)-2418.18%
Revenue 1Y (TTM)34.06%

HEB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 60% to HEB. The Buy consensus is the average rating of analysts ratings from 1 analysts.


Ownership
Inst Owners1.4%
Ins Owners61.86%
Short Float %N/A
Short RatioN/A
Analysts
Analysts60
Price TargetN/A
EPS Next Y-100%
Revenue Next YearN/A